November 2025 in “Mendeley Data” This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.
November 2025 in “Mendeley Data” In this study, tofacitinib and baricitinib showed comparable efficacy and tolerability under unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe alopecia areata over 24 weeks; however, the unorthodox baricitinib regimen yielded a lower effectiveness in severe cases, emphasizing the importance of adherence to guideline-recommended dosing.
1265 citations
,
October 2013 in “The Journal of Clinical Endocrinology and Metabolism” This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.
18 citations
,
September 2023 in “Nutrition Research Reviews” In this scoping review, researchers found that while some dietary approaches may help improve psoriasis symptoms—particularly in those with obesity or coeliac disease—the overall evidence is limited, and larger studies are necessary to identify effective diets for the broader psoriasis population.
8 citations
,
April 2020 in “Facial Plastic Surgery Clinics of North America” This abstract explains that androgenetic alopecia, a common hair loss disorder influenced by genetics and hormones like dihydrotestosterone, has FDA-approved treatments including minoxidil, finasteride, and photolaser therapy, but its genetic basis and susceptibility to environmental factors remain complex.